Phase II trial of mitomycin, vindesine, and hexamethylmelamine in metastatic non-small cell bronchogenic carcinoma.

Abstract

Mitomycin (10 mg/m2 iv on Day 1), vindesine (3 mg/m2 iv on Days 1 and 8), and hexamethylmelamine (100 mg/m2/day orally on Days 1-14) was administered to 32 patients with metastatic non-small cell bronchogenic carcinoma. No patient had been previously treated with chemotherapy and Eastern Cooperative Oncology Group (ECOG) performance status was 0-1 in 21 of 32 patients. Eleven partial responses (34%) were observed, with a median duration of 9 weeks. No complete responses were observed in this group of patients, whose median survival duration was 22 weeks. Moderate leukopenia (median leukocyte count nadir, 2500/mm3) was the major toxic effect. Although this regimen is active and relatively nontoxic, it will not be utilized in future ECOG trials because it has not produced an apparent improvement in survival duration.

• Authors: P D Bonomi, R Pazdur, L Stolbach, B Mason, D Ettinger
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 70 Issue 12 Pg. 1447-8 (Dec 1986) ISSN: 0361-5960 [Print] United States
• PMID: 3024827 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Mitomycins
• Altretamine
• Vindesine

Topics

• Adult
• Aged
• Altretamine (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Carcinoma, Bronchogenic (drug therapy)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Drug Evaluation
• Female
• Humans
• Lung Neoplasms (drug therapy)
• Male
• Middle Aged
• Mitomycins (administration & dosage)
• Neoplasm Metastasis
• Vindesine (administration & dosage)